Specialty Drug Trends: A Growing Concern for Payers
Executives from Prime Therapeutics discussed the future of specialty drugs at AMCP Nexus, highlighting key areas such as autoimmune therapies, multiple sclerosis treatments, and cell and gene therapy challenges.
Specialty drugs remain a top spending concern, with employers predicting a 9% increase in healthcare costs for 2026, according to the Business Group on Health's Employer Health Care Strategy Survey.
A major cost driver is cancer care, with increased spending due to growing cancer diagnoses and escalating costs for the fourth consecutive year.
- Over 1,000 novel drugs have been launched globally in the last 20 years.
- Almost 400 novel drugs have been launched in the past five years.
- 48 novel drugs were launched in the US in 2024, a 22% increase from 2015-2019.
Specialty biologic drugs are expected to significantly impact spending, making them a key concern for payers.
No specific quote available.
Author's summary: Payers face growing costs from specialty drugs, including cancer care and biologics.
More News
- Bitches in Stitches: Northern Quarter's new all-female comedy shows - Mancunian Matters
- Ayuba Sylvester James: “For MCP to Rise, Chakwera Must Fall” - Malawi Nyasa Times - News from Malawi about Malawi
- Over 580,000 Blood Pressure Medication Bottles Recalled, FDA Reports
- Florence + The Machine - Everybody Scream Review
- From Trump, With Impunity
- GPSC Recruitment 2025: Registration Process For 44 Assistant Professor Ends Soon; Check Age Limit Here
- 'Thief VR: Legacy of Shadow' Comes to All Major VR Headsets in December, New Gameplay Here